The diagnostic value of lipoprotein-related phospholipase A2 and matrix metalloproteinase-9 in identifying patients with coronary plaque or stenosis

1 Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, et al. ACC/AHA guidelines for coronary angiog raphy. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol. 1999;33:1756-824. DOI: 10.1016/S0735-1097(99)00126-6 Search in Google Scholar

2 Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011; 123: 18-209 DOI: 10.1161/CIR.0b013e3182009701 Search in Google Scholar

3 Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM. 2006; 56: 967-976. Search in Google Scholar

4 Eriksson EE, Xie X, Werr J, Thoren P, Lindbom L. Importance of primary capture and L-selectindependent secondary capture in leukocyte accumulation in inflammation and atherosclerosis in vivo. J Exp Med. 2001;194:205-18. DOI: 10.1084/jem.194.2.205 Search in Google Scholar

5 Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A. 1995;92:8264-8. DOI: 10.1073/pnas.92.18.8264 Search in Google Scholar

6 Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1995;92:3893-7. DOI: 10.1073/pnas.92.9.3893 Search in Google Scholar

7 Chen L, Chester MR, Redwood S, Huang J, Leatham E, Kaski JC. Angiographic stenosis progression and coronary events in patients with ‘stabilized’ unstable angina. Circulation. 1995;91:2319-24 DOI: 10.1161/01.CIR.91.9.2319 Search in Google Scholar

8 Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997;336:1276-82 DOI: 10.1056/NEJM199705013361802 Search in Google Scholar

9 Fukuda D, Shimada K, Tanaka A, Kusuyama T, Yamashita H, Virmani R. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris.Am J Cardiol. 2006 Jan 15;97 (2):175-80. DOI: 10.1016/j.amjcard.2005.08.020 Search in Google Scholar

10 Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006; 354: 1264-1272. DOI: 10.1056/NEJMoa054013 Search in Google Scholar

11 Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, et al. Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem. 2010; Jun;56(6):967-76. DOI: 10.1373/clinchem.2009.137489 Search in Google Scholar

12 Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, et al. C-reative protein in the arterial intima: rol of C-reative protein receptor-dependent monocyte recruitment in atherogenenesis. Arterioscler Thromb Vase Biol. 2000; 20:2094-9. DOI: 10.1161/01.ATV.20.9.2094 Search in Google Scholar

13 Oei H-H S, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MMB, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke. The Rotterdam Study. Circulation. 2005;111:570-575. DOI: 10.1161/01.CIR.0000154553.12214.CD Search in Google Scholar

14 Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degredation of platelet-activating factor. J Biol Chem. 1987;262:4215-4222. DOI: 10.1016/S0021-9258(18)61335-3 Search in Google Scholar

15 Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD, et al. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem. 2005;51: 2264-2273. DOI: 10.1373/clinchem.2005.058404 Search in Google Scholar

16 Persson M, Nilsson J-A, Nelson JJ, Berglund G. The epidemiology of Lp-PLA2: distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis. 2007;190:388-396 DOI: 10.1016/j.atherosclerosis.2006.02.016 Search in Google Scholar

17 Budoff MJ, Achenbach S, Duerinckx A. Clinical utility of computed tomography and magnetic resonance techniques for noninvasive coronary angiography. J Am Coll Cardiol. 2003; 42:1867-78. DOI: 10.1016/j.jacc.2003.07.018 Search in Google Scholar

18 Achenbach S, Ropers D, Hoffmann U. Assessment of coronary remodeling in stenotic and nonstenotic coronary atherosclerotic lesions by multidetector spiral computed tomography. J Am Coll Cardiol. 2004; 43: 842-7. DOI: 10.1016/j.jacc.2003.09.053 Search in Google Scholar

19 White CS, Kuo D. Chest pain in the emergency department: role of multidetector CT. Radiology. 2007; 245: 672-81. DOI: 10.1148/radiol.2453061481 Search in Google Scholar

20 Schuijf JD, Jukema JW, van der Wall EE, Bax JJ. Multi-slice computed tomography in the evaluation of patients with acute chest pain. Acute Card Care. 2007; 9: 214-21. DOI: 10.1080/17482940701589275 Search in Google Scholar

21 Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999; 138 (52): 19-20. DOI: 10.1016/S0002-8703(99)70266-8 Search in Google Scholar

22 Koenig W, Löwel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the framingham score : ımplications for future risk assessment: results from a large cohort study in Southern Germany. Circulation. 2004;109:1349-1353. DOI: 10.1161/01.CIR.0000120707.98922.E3 Search in Google Scholar

23 Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006; 26:2523-2529. DOI: 10.1161/01.ATV.0000244681.72738.bc Search in Google Scholar

24 Schoenhagen P, McErlean ES, Nissen SE. The vulnerable coronary plaque. J Cardiovasc Nurs. 2000 Oct;15(1):1-12. DOI: 10.1097/00005082-200010000-00002 Search in Google Scholar

25 Nishikura T, Koba S, Yokota Y, Hirano T, Tsunoda F, Shoji M, et al. Elevated small dense low-density lipoprotein cholesterol as a predictor for future cardiovascular events in patients with stable coronary artery diseaseJ Atheroscler Thromb. 2014;21 (8):755-67. DOI: 10.5551/jat.23465 Search in Google Scholar

26 Kunutsor SK, Zaccardi F, Karppi J, Kurl S, Laukkanen JA. Is High Serum LDL/HDL Cholesterol Ratio an Emerging Risk Factor for Sudden Cardiac Death. Findings from the KIHD Study J Atheroscler Thromb. 2017 Jun 1;24 (6):600-608. DOI: 10.5551/jat.37184 Search in Google Scholar

27 Moriyama K, Takahashi E. Non-HDL Cholesterol is a More Superior Predictor of Small-Dense LDL Cholesterol than LDLCholesterol in Japanese Subjects with TG Levels <400 mg/dL. J Atheroscler Thromb. 2016 Sep 1;23 (9):1126-37. DOI: 10.5551/jat.33985 Search in Google Scholar

28 Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF. Cardiovascular events with increased lipoprotein-associated phospholipase A (2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.Arterioscler Thromb Vasc Biol. 2008 Jun;28 (6):1172-8. DOI: 10.1161/ATVBAHA.107.160739 Search in Google Scholar

29 Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008;101:51-50. DOI: 10.1016/j.amjcard.2008.04.018 Search in Google Scholar

30 Lerman A, McConnell JP. Lipoprotein-associated phospholipase A2: A risk marker or a risk factor? Am J Cardiol. 2008;101:11-22. DOI: 10.1016/j.amjcard.2008.04.014 Search in Google Scholar

31 Ferri N, Paoletti R, Corsini A. Lipid-modified proteins as biomarkers for cardiovascular disease: a review. Biomarkers. 2005 Jul-Aug;10 (4):219-37. DOI: 10.1080/13547500500216660 Search in Google Scholar

32 Segers D, Helderman F, Cheng C, van Damme LC, Tempel D, Boersma E, et al. Gelatinolytic activity in atherosclerotic plaques is highly localized and is associated with both macrophages and smooth muscle cells in vivo. Circulation. 2007;115:609-16. DOI: 10.1161/CIRCULATIONAHA.106.636415 Search in Google Scholar

33 Chen Y, Fu Y, Wang S, Chen P, Pei Y, Zhang J, et al. Clinical significance of neutrophil gelatinase-associated lipocalin and sdLDL-C for coronary artery disease in patients with type 2 diabetes mellitus aged ≥ 65 years. Cardiovasc Diabetol. 2022 Nov 17;21(1):252. DOI: 10.1186/s12933-022-01668-5 Search in Google Scholar

34 Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 Jan 28;107(3):499-511. DOI: 10.1161/01.CIR.0000052939.59093.45 Search in Google Scholar

35 Liu H, Yao Y, Wang Y, Ji L, Zhu K, Hu H. Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis: A cross-sectional study. J Cell Mol Med. 2018 Oct;22(10):5145-5150. DOI: 10.1111/jcmm.13803 Search in Google Scholar

36 Schaloske RH, Dennis EA. The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta. 2006; 1761: 1246-59 DOI: 10.1016/j.bbalip.2006.07.011 Search in Google Scholar

37 Daniels LB, Laughlin GA, Mark J, Bettencourt R, Wolfert RL, Barrett-Connor E. Lipoprotein -associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apperently healthy older populatıon: the Rancho Bernardo study. J Am Coll Cardiol. 2008; 51: 913-919. DOI: 10.1016/j.jacc.2007.10.048 Search in Google Scholar

38 Hyemoon C, Hyuck Moon K, Jong-Youn K, Young Won Y, Rhee J, Choi EY, et al.Lipoprotein-Associated Phospholipase A2 Is Related to Plaque Stability and Is a Potential Biomarker for Acute Coronary Syndrome. Yonsei Med J 55(6):1507-1515, 2014. DOI: 10.3349/ymj.2014.55.6.1507 Search in Google Scholar

39 Maiolino G, Bisogni V, Rossitto G, Rossi GP. Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.World J Cardiol. 2015 Oct 26;7 (10):609-20. DOI: 10.4330/wjc.v7.i10.609 Search in Google Scholar

40 Tooran A, Soudabeh F, Toktam Kazemi F, Reza F, Rahim R, Movahedi M, et al. Evaluation of MMP-9, IL-6, TNF-α levels and peripheral blood mononuclear cells genes expression of MMP-9 and TIMP-1 in Iranian patients with coronary artery disease. Cardiovasc Thorac Res. 2023, 15(4), 223-230. DOI: 10.34172/jcvtr.2023.31844 Search in Google Scholar

41 Liu B, Su L, Loo SJ, Gao Y, Khin E, Kong X, et al. Matrix metallopeptidase 9 contributes to the beginning of plaque and is a potential biomarker for the early identification of atherosclerosis in asymptomatic patients with diabetes. Front Endocrinol (Lausanne). 2024 Apr 10;15:1369369. DOI: 10.3389/fendo.2024.1369369. Search in Google Scholar